+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The impact of CMV prevention on long-term recipient and graft survival in heart transplant recipients: analysis of the Scientific Registry of Transplant Recipients (SRTR) database



The impact of CMV prevention on long-term recipient and graft survival in heart transplant recipients: analysis of the Scientific Registry of Transplant Recipients (SRTR) database



Clinical Transplantation 25(4): E455



The association between cytomegalovirus immunoglobulin (CMVIG) and long-term clinical outcomes in heart transplantation has not been evaluated using data from large national databases. We examined the association between CMVIG, with and without antivirals, or antivirals alone, and long-term recipient and graft survival in heart transplantation using data from the Scientific Registry of Transplant Recipients. Recipients transplanted between January 1995 and October 2008, ≤80 yr old, of primary, single-organ heart transplants, recorded as receiving CMVIG with or without antivirals (n = 2112), antivirals without CMVIG (n = 12 089), or no prophylaxis (n = 14 661), at hospital discharge, were included. Kaplan-Meier analysis was used to examine death and graft loss at seven yr post-transplantation; Cox proportional hazards regression was used to estimate the adjusted risk of graft loss and death for prophylaxis vs. no prophylaxis. CMVIG use (± other antivirals) was associated with increased recipient (69% vs. 64%, p < 0.001) and graft (67% vs. 63%, p < 0.001) survival. Antivirals alone also demonstrated increased recipient (68% vs. 64%, p < 0.001) and graft survival (66% vs. 63%, p < 0.001). Cox models demonstrated that CMVIG (± other antivirals) was independently associated with decreased risk for death (hazard ratio, HR 0.79, p < 0.001) and graft loss (HR 0.78, p < 0.001) as were antivirals alone (mortality HR: 0.79, p < 0.001; graft loss: HR 0.78, p < 0.001).

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036113984

Download citation: RISBibTeXText

PMID: 21504474

DOI: 10.1111/j.1399-0012.2011.01459.x


Related references

Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transplantation 18(9): 1029-1036, 2012

Cytomegalovirus prevention and long-term recipient and graft survival in pediatric heart transplant recipients. Transplantation 90(12): 1432-1438, 2010

Impact of sirolimus and tacrolimus on mortality graft loss in liver transplant recipients with and without HCV ? an analysis of the SRTR database. 2012

Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients. Transplant Infectious Disease 21(1): E13015, 2019

Variables of importance in the Scientific Registry of Transplant Recipients database predictive of heart transplant waitlist mortality. American Journal of Transplantation 19(7): 2067-2076, 2019

Predicting early and long term patient and graft survival for liver transplant recipients with HCV infection Results of the NIDDK liver transplant database. Hepatology 36(4 Part 2): 177A, 2002

Small Split Pediatric Kidneys to Expand the Donor Pool: An Analysis of Scientific Registry of Transplant Recipients (SRTR) Data. Transplantation 103(12): 2549-2557, 2019

Survival rates after liver transplantation using hypertensive donor grafts: an analysis of the Scientific Registry of Transplant Recipients database. Journal of Hepato-Biliary-Pancreatic Sciences 24(8): 441-448, 2017

Impact of donor age on graft survival among liver transplant recipients Analysis of the UNOS database. Hepatology 34(4 Pt 2): 195A, 2001

Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients. Transplant Infectious Disease 20(5): E12964, 2018

Preoperative Toxoplasma gondii serostatus does not affect long-term survival of cardiac transplant recipients. Analysis of the Spanish Heart Transplantation Registry. International Journal of Cardiology 250: 183-187, 2018

Long-term outcomes of heart transplant recipients with hepatitis C positivity: the data from the U.S. transplant registry. Clinical Transplantation 30(12): 1570-1577, 2016

Adult-age donors offer acceptable long-term survival to pediatric heart transplant recipients: an analysis of the United Network of Organ Sharing database. Journal of Thoracic and Cardiovascular Surgery 132(5): 1208-1212, 2006

Comparing Scientific Registry of Transplant Recipients posttransplant program-specific outcome ratings at listing with subsequent recipient outcomes after transplant. American Journal of Transplantation 19(2): 391-398, 2019

The prevalence of VDRL-positive donors and impact on graft survival in liver transplant recipients Analysis of the UNOS database. Hepatology 34(4 Pt 2): 647A, 2001